Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPS NASDAQ:IMMX NASDAQ:LKFT NASDAQ:OCUL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCompass Pathways$12.08+5.9%$9.46$2.25▼$14.76$1.54B2.54.00 million shs2.51 million shsIMMXImmix Biopharma$8.45+4.3%$9.22$1.94▼$11.61$440.73M0.11.48 million shs1.11 million shsLKFTLakefront Biotherapeutics American Depositary Shares$28.90-0.1%$28.23$26.42▼$37.78$1.91B0.26175,647 shs91,349 shsOCULOcular Therapeutix$8.94+2.8%$8.90$6.23▼$16.44$1.90B0.892.37 million shs2.70 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCompass Pathways+3.45%-12.57%+21.77%+78.56%+148.58%IMMXImmix Biopharma-0.98%-3.80%-24.02%-19.00%+233.33%LKFTLakefront Biotherapeutics American Depositary Shares+1.15%+2.95%+5.89%-8.74%+2.08%OCULOcular Therapeutix-0.46%-1.14%-5.02%-0.68%-1.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCompass Pathways$12.08+5.9%$9.46$2.25▼$14.76$1.54B2.54.00 million shs2.51 million shsIMMXImmix Biopharma$8.45+4.3%$9.22$1.94▼$11.61$440.73M0.11.48 million shs1.11 million shsLKFTLakefront Biotherapeutics American Depositary Shares$28.90-0.1%$28.23$26.42▼$37.78$1.91B0.26175,647 shs91,349 shsOCULOcular Therapeutix$8.94+2.8%$8.90$6.23▼$16.44$1.90B0.892.37 million shs2.70 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCompass Pathways+3.45%-12.57%+21.77%+78.56%+148.58%IMMXImmix Biopharma-0.98%-3.80%-24.02%-19.00%+233.33%LKFTLakefront Biotherapeutics American Depositary Shares+1.15%+2.95%+5.89%-8.74%+2.08%OCULOcular Therapeutix-0.46%-1.14%-5.02%-0.68%-1.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPSCompass Pathways 2.93Moderate Buy$21.3676.85% UpsideIMMXImmix Biopharma 2.50Moderate Buy$19.50130.77% UpsideLKFTLakefront Biotherapeutics American Depositary Shares 2.13Hold$36.5026.30% UpsideOCULOcular Therapeutix 2.79Moderate Buy$23.78165.97% UpsideCurrent Analyst Ratings BreakdownLatest IMMX, OCUL, CMPS, and LKFT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026LKFTLakefront Biotherapeutics American Depositary Shares Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold6/1/2026CMPSCompass Pathways TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/26/2026LKFTLakefront Biotherapeutics American Depositary Shares Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/22/2026IMMXImmix Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.005/22/2026CMPSCompass Pathways Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026CMPSCompass Pathways HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026CMPSCompass Pathways Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/15/2026CMPSCompass Pathways Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $20.005/14/2026CMPSCompass Pathways Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$16.00 ➝ $17.005/14/2026CMPSCompass Pathways Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$21.00 ➝ $22.005/13/2026CMPSCompass Pathways BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPSCompass PathwaysN/AN/AN/AN/A($0.55) per shareN/AIMMXImmix BiopharmaN/AN/AN/AN/A$1.77 per shareN/ALKFTLakefront Biotherapeutics American Depositary Shares$1.26B1.51$0.73 per share39.86$47.57 per share0.61OCULOcular Therapeutix$51.95M37.68N/AN/A$3.07 per share2.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPSCompass Pathways-$287.86M-$3.15N/AN/AN/AN/A-31.07%-11.40%7/30/2026 (Estimated)IMMXImmix Biopharma-$29.44M-$0.92N/AN/AN/AN/A-73.24%-59.20%8/14/2026 (Estimated)LKFTLakefront Biotherapeutics American Depositary Shares$363.05M-$1.41N/AN/AN/AN/AN/AN/A8/10/2026 (Estimated)OCULOcular Therapeutix-$265.94M-$1.46N/AN/AN/A-558.24%-64.28%-48.15%8/4/2026 (Estimated)Latest IMMX, OCUL, CMPS, and LKFT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026CMPSCompass Pathways-$0.45-$0.30+$0.15-$0.30N/AN/A5/7/2026Q1 2026IMMXImmix Biopharma-$0.1909-$0.18+$0.0109-$0.18N/AN/A5/6/2026Q1 2026LKFTLakefront Biotherapeutics American Depositary Shares-$1.27$0.25+$1.52$0.25$11.26 million$8.75 million3/25/2026Q4 2025IMMXImmix Biopharma-$0.16-$0.28-$0.12-$0.28N/AN/A3/24/2026Q4 2025CMPSCompass Pathways-$0.41-$1.00-$0.59-$1.00N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCMPSCompass PathwaysN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/ALKFTLakefront Biotherapeutics American Depositary SharesN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPSCompass Pathways0.153.323.32IMMXImmix BiopharmaN/A8.758.75LKFTLakefront Biotherapeutics American Depositary SharesN/A30.4830.30OCULOcular Therapeutix0.1214.8114.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPSCompass Pathways46.19%IMMXImmix Biopharma11.26%LKFTLakefront Biotherapeutics American Depositary Shares32.46%OCULOcular Therapeutix59.21%Insider OwnershipCompanyInsider OwnershipCMPSCompass Pathways2.82%IMMXImmix Biopharma30.30%LKFTLakefront Biotherapeutics American Depositary Shares2.91%OCULOcular Therapeutix2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPSCompass Pathways120134.95 million131.14 millionOptionableIMMXImmix Biopharma954.41 million37.92 millionOptionableLKFTLakefront Biotherapeutics American Depositary Shares1,31065.90 million63.98 millionOptionableOCULOcular Therapeutix230218.96 million213.92 millionOptionableIMMX, OCUL, CMPS, and LKFT HeadlinesRecent News About These CompaniesOcular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 8, 2026 | americanbankingnews.comAssessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price VolatilityJune 6, 2026 | finance.yahoo.comOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2026 | globenewswire.comOcular Therapeutix, Inc. to Participate in Clinical Trials at the Summit 2026 in Las VegasJune 4, 2026 | quiverquant.comQOcular Therapeutix™ to Participate in Clinical Trials at the Summit 2026June 4, 2026 | globenewswire.comOcular Therapeutix™ to Host Investor Day on June 17, 2026June 2, 2026 | globenewswire.comOcular Therapeutix (NASDAQ:OCUL) Insider Sells $15,235.60 in StockMay 29, 2026 | insidertrades.comOcular Therapeutix Shrinking The Burden Of BlindnessMay 28, 2026 | bloomberg.comAcuta Capital Sells 56% of Ocular Therapeutix Shares in Q1May 27, 2026 | finance.yahoo.comOcular Therapeutix Inc (OCUL)May 24, 2026 | investing.comWhat This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for InvestorsMay 20, 2026 | finance.yahoo.comOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 15, 2026 | globenewswire.comOcular Therapeutix, Inc. $OCUL Shares Bought by Empire Life Investments Inc.May 13, 2026 | marketbeat.comOcular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comDole posts downbeat Q1 earnings, joins Ocular Therapeutix and other big stocks moving lower in Monday's pre-market sessionMay 11, 2026 | msn.comOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8, 2026 | globenewswire.comOcular: SOL-1 Success Is Real, But Adoption Risks Keep Me At HoldMay 8, 2026 | seekingalpha.comOcular Therapeutix Starts SOL-X Trial As AXPAXLI Data And Valuation DivergeMay 8, 2026 | finance.yahoo.comOcular Therapeutix (OCUL) Gets a Buy from H.C. WainwrightMay 6, 2026 | theglobeandmail.comWhy Ocular Therapeutix (OCUL) Stock Is NosedivingMay 6, 2026 | theglobeandmail.comAssessing Ocular Therapeutix (OCUL) Valuation As Axpaxli Expectations Meet Volatile ReturnsMay 6, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMMX, OCUL, CMPS, and LKFT Company DescriptionsCompass Pathways NASDAQ:CMPS$12.08 +0.67 (+5.87%) Closing price 04:00 PM EasternExtended Trading$12.13 +0.05 (+0.41%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Immix Biopharma NASDAQ:IMMX$8.45 +0.35 (+4.32%) Closing price 04:00 PM EasternExtended Trading$8.45 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT$28.90 -0.04 (-0.14%) As of 04:00 PM EasternGalapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Ocular Therapeutix NASDAQ:OCUL$8.94 +0.24 (+2.76%) Closing price 04:00 PM EasternExtended Trading$8.82 -0.12 (-1.35%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
